NASDAQ:MDCO - The Medicines Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $33.25 -0.43 (-1.28 %) (As of 05/23/2019 08:37 AM ET)Previous Close$33.68Today's Range$32.46 - $33.6552-Week Range$16.69 - $41.57Volume1.28 million shsAverage Volume1.10 million shsMarket Capitalization$2.46 billionP/E RatioN/ADividend YieldN/ABeta1.36 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey. Receive MDCO News and Ratings via Email Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MDCO Previous Symbol CUSIP58468810 CIK1113481 Webhttp://www.themedicinescompany.com/ Phone973-290-6000Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.14 million Price / Sales400.19 Cash FlowN/A Price / Cash FlowN/A Book Value($1.02) per share Price / Book-32.60Profitability EPS (Most Recent Fiscal Year)($2.91) Net Income$-123,160,000.00 Net MarginsN/A Return on Equity-2,118.72% Return on Assets-25.39%Miscellaneous Employees62 Outstanding Shares73,900,000Market Cap$2.46 billion Next Earnings Date8/7/2019 (Estimated) OptionableOptionable The Medicines (NASDAQ:MDCO) Frequently Asked Questions What is The Medicines' stock symbol? The Medicines trades on the NASDAQ under the ticker symbol "MDCO." How were The Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) issued its earnings results on Thursday, April, 25th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.09. The firm's quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the company earned ($0.76) EPS. View The Medicines' Earnings History. When is The Medicines' next earnings date? The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for The Medicines. What price target have analysts set for MDCO? 9 equities research analysts have issued 12-month target prices for The Medicines' stock. Their forecasts range from $38.00 to $110.00. On average, they anticipate The Medicines' share price to reach $64.25 in the next year. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for The Medicines. What is the consensus analysts' recommendation for The Medicines? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines. Has The Medicines been receiving favorable news coverage? Press coverage about MDCO stock has trended positive this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. The Medicines earned a coverage optimism score of 2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. Who are some of The Medicines' key competitors? Some companies that are related to The Medicines include Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG) and Nektar Therapeutics (NKTR). What other stocks do shareholders of The Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include Gilead Sciences (GILD), Cisco Systems (CSCO), Alibaba Group (BABA), Celgene (CELG), AbbVie (ABBV), Micron Technology (MU), Incyte (INCY), Intel (INTC), Intercept Pharmaceuticals (ICPT) and NVIDIA (NVDA). Who are The Medicines' key executives? The Medicines' management team includes the folowing people: Mr. Mark Timney, CEO & Director (Age 54)Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)Dr. Goutham Krishna Gorti, VP & Head of Investor Relations Who are The Medicines' major shareholders? The Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (7.16%), Iridian Asset Management LLC CT (5.17%), Maverick Capital Ltd. (5.16%), Macquarie Group Ltd. (2.31%), Northern Trust Corp (1.17%) and Elk Creek Partners LLC (1.03%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman and William Crouse. View Institutional Ownership Trends for The Medicines. Which institutional investors are selling The Medicines stock? MDCO stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., First Midwest Bank Trust Division, Pinebridge Investments L.P., Rhenman & Partners Asset Management AB, Principal Financial Group Inc., Pinnacle Associates Ltd., Elk Creek Partners LLC and State of Tennessee Treasury Department. Company insiders that have sold The Medicines company stock in the last year include Clive Meanwell and Melvin K Spigelman. View Insider Buying and Selling for The Medicines. Which institutional investors are buying The Medicines stock? MDCO stock was acquired by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Iridian Asset Management LLC CT, Maverick Capital Ltd., Coronation Fund Managers Ltd., Assenagon Asset Management S.A., Marshall Wace North America L.P., New York State Common Retirement Fund and First Eagle Investment Management LLC. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines. How do I buy shares of The Medicines? Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is The Medicines' stock price today? One share of MDCO stock can currently be purchased for approximately $33.25. How big of a company is The Medicines? The Medicines has a market capitalization of $2.46 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe. What is The Medicines' official website? The official website for The Medicines is http://www.themedicinescompany.com/. How can I contact The Medicines? The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected] MarketBeat Community Rating for The Medicines (NASDAQ MDCO)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 454 (Vote Outperform)Underperform Votes: 333 (Vote Underperform)Total Votes: 787MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Quiet Period Expirations Explained Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.